CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma
Abstract CD96 is a promising candidate for immunotherapy. However, its role and importance in glioma remains unknown. We thus aimed to genetically and clinically characterize CD96 expression in gliomas. For this, we extracted RNA-seq data of 699 glioma samples from the TCGA dataset and validated the...
Guardado en:
Autores principales: | Fangkun Liu, Jing Huang, Fengqiong He, Xiaodong Ma, Fan Fan, Ming Meng, Yang Zhuo, Liyang Zhang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cc2f23111ef7425386ea78d03e4895fc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
por: Katrin Aslan, et al.
Publicado: (2020) -
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
por: Haoxin Li, et al.
Publicado: (2019) -
Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade
por: Chisato Ohe, et al.
Publicado: (2021) -
The clinical features, prognostic significance, and immune heterogeneity of CD37 in diffuse gliomas
por: Xuejun Yan, et al.
Publicado: (2021) -
The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis
por: Amina Ghouzlani, et al.
Publicado: (2021)